noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

University of Colorado at Boulder

How to fight ‘technostress’ at work
MPDC - Metropolitan Police Department

Arrest Made in Northwest Sexual Abuse Offenses
Rolls-Royce North America Inc.

Rolls Royce agrees to sell Naval Propulsors & Handling business to[...]

Healthcare

TCS - Tata Consultancy Services Ltd.

08/02/2022 | Press release | Distributed by Public on 08/02/2022 02:17

TCS Named a Leader in Life Sciences Operations by Everest Group

Tata Consultancy Services Placed Highest for its Vision and Capabilities; Breadth of Life Science Services, Investments in Analytics and Automation Solutions, and the TCS ADD™ Platform, Cited as Key Strengths

NEW YORK | MUMBAI, August 1, 2022: Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS) has been positioned as a Leader in Everest Group's PEAK Matrix® on Life Sciences Operations¹ , placed highest for its Vision and Capabilities in an assessment of 32 life sciences BPS providers.

The report said that TCS offers a wide spectrum of services across the entire life sciences value chain, with pharmacovigilance, clinical data management, and commercial operations with marketing and sales support and effectiveness, being its focus areas.

Cited as key strengths are its platform-based TCS ADD™ suite of solutions as well as the company's recent investments in analytics (TCS Next Best Action - commercial insights) and automation solutions (Clinical Trial Data Entry Assistant and Case Tracker Automation) that have enhanced its digital portfolio. It goes on to say that TCS has been making notable investments in improving its process and people capabilities, one example being the TCS' Pharma Academy of Learning and Sharing.

"Progressive life sciences companies are partnering with TCS to embrace next-gen technologies and platforms to enhance innovation, provide patient-centric care, drive growth and realize their ambitions," said Vikram Karakoti, Global Head, Digital Medicine and Medical Technologies, Business Transformation Group, TCS. "This leadership position is a reflection of our vision and strategy, capabilities, investments in research, innovation and intellectual property, and the resultant market impact."

TCS offers comprehensive advisory and services and solutions including data and analytics, predictive and prescriptive analytics, cognitive search, genomics research, advanced cloud-based platform solutions, and digital labs. Early investments in research and innovation around key trends and intellectual property have helped TCS gain significant scale and depth across the value chain.

TCS offers a full set of business operations, transformation services and solutions including clinical operations, laboratory platforms, pharmacovigilance, regulatory services, medical articles and medico marketing. The company provides clinical research services such as clinical data management, risk-based monitoring, biostatistics and programming, medical writing, medical affairs and health economics and outcomes research.

TCS' extensive portfolio of intellectual property - including the award-winning TCS ADD platform suite, Decision Fabric™ engine, TCS Connected Clinical Trials™ platform, Real World Evidence platform, and Translational Research Platform - helps customers achieve superior business outcomes and increased speed to market. Other solutions include Custom Functions Framework, CDISC Review Assistant, and eTMF Indexing Assistant for Clinical Trials, MLR automation and PromoRev for marketing and sales, analytics and compliance support, and Data and Analytics Target Operating Model (DATOM™) for operations spanning the complete supply chain.

The TCS ADD cloud-based platform suite helps global life sciences companies streamline the entire clinical R&D value chain, spanning clinical data management, metadata management, pharmacovigilance, risk-based monitoring, patient engagement, clinical operations, and data analytics and insights.

"An increasing focus on safety, transition to an omnichannel approach for patient interactions, and growing appetite for digital tools are encouraging enterprises to seek external support to keep pace with the evolving landscape of the life sciences industry," said Abhishek AK, Practice Director, Everest Group. "A wide range of service offerings across the life sciences value chain with focus on pharmacovigilance, clinical data management, and commercial operations, large scale operations, and investments in analytics and automation solutions to enhance its digital offerings made TCS a Leader on Everest Group's Life Sciences Operations PEAK Matrix® Assessment 2022."

¹Life Sciences Operations PEAK Matrix Assessment 2022, Manu Aggarwal, Everest Group, June 23, 2022

About Tata Consultancy Services (TCS)

Tata Consultancy Services is an IT services, consulting and business solutions organization that has been partnering with many of the world's largest businesses in their transformation journeys for over 50 years. TCS offers a consulting-led, cognitive powered, integrated portfolio of business, technology and engineering services and solutions. This is delivered through its unique Location Independent Agile™ delivery model, recognized as a benchmark of excellence in software development.

A part of the Tata group, India's largest multinational business group, TCS has over 606,000 of the world's best-trained consultants in 55 countries. The company generated consolidated revenues of US $25.7 billion in the fiscal year ended March 31, 2022, and is listed on the BSE (formerly Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. TCS' proactive stance on climate change and award-winning work with communities across the world have earned it a place in leading sustainability indices such as the MSCI Global Sustainability Index and the FTSE4Good Emerging Index. For more information, visit www.tcs.com